Sign In
Buy RGEN
$121.73
+0.600 (+0.495%)
At Close: Jun 03, 2026
Repligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
10:32am, Thursday, 04'th Sep 2025
Repligen Corporation (NASDAQ:RGEN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Olivier Loeillot - President, CEO & Director Jason Garland - C
mRNA Biotechs - Long-Term Value Risks Abound
06:20am, Thursday, 28'th Aug 2025
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c
Repligen Corporation to Present at Upcoming September Conferences
07:30am, Friday, 22'nd Aug 2025
WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending
Repligen Corporation: Still Navigating Through The Covid Cliff
03:24pm, Thursday, 14'th Aug 2025
Repligen Corporation's Q2 results beat revenue expectations driven by strong revenue growth from consumables and biopharma sales. The company has diversified its product portfolio and customer base th
Repligen Stock Outlook: Risk Skewed To The Downside Through 2026
10:45am, Thursday, 31'st Jul 2025
Repligen RGEN has been in a steady downtrend for over 1400 days. Adhishthana principles suggest the weakness is likely to continue.
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
07:30am, Thursday, 31'st Jul 2025
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have
Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript
05:31pm, Tuesday, 29'th Jul 2025
Repligen Corporation (NASDAQ:RGEN ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jacob Johnson - Corporate Participant Jason K. Garland - CFO & Chief Compliance Offic
Repligen (RGEN) Lags Q2 Earnings Estimates
09:46am, Tuesday, 29'th Jul 2025
Repligen (RGEN) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.33 per share a year ago.
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
07:30am, Tuesday, 29'th Jul 2025
WALTHAM, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its s
Here's Why Repligen (RGEN) is a Strong Growth Stock
10:46am, Monday, 21'st Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Repligen to Report Second Quarter 2025 Financial Results
07:30am, Thursday, 17'th Jul 2025
Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET
908 Devices Appoints Christopher D. Brown to its Board of Directors
08:00am, Monday, 16'th Jun 2025
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President,
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
12:36pm, Thursday, 29'th May 2025
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report
07:30am, Tuesday, 27'th May 2025
WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of
Repligen Corporation to Present at Upcoming May Investor Conferences
07:30am, Wednesday, 07'th May 2025
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participati
